Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 2/20 | 0.39 |
| ▸ | CTRC | Q99895 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | CTSG | P08311 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9450640 | 0.71 | PRSS1 (0.39) | PRSS1CTRCF2ALDH1A1 | |
| SCHEMBL9450639 | 0.71 | PRSS1 (0.39) | PRSS1CTRCF2ALDH1A1 | |
| SCHEMBL9450611 | 0.71 | PRSS1 (0.39) | PRSS1CTRCF2ALDH1A1 | |
| SCHEMBL19441223 | 0.69 | PRSS1 (0.38) | PRSS1CTRCF2ELANECTSG | |
| SCHEMBL14883094 | 0.69 | KMT2A (0.42) | PRSS1CTRCF2ALDH1A1ELANE | |
| SCHEMBL577431 | 0.69 | KMT2A (0.42) | PRSS1CTRCF2ALDH1A1ELANE | |
| SCHEMBL14882894 | 0.69 | PRSS1 (0.38) | PRSS1CTRCF2ELANECTSG | |
| SCHEMBL9487973 | 0.69 | PRSS1 (0.38) | PRSS1CTRCF2ELANECTSG | |
| SCHEMBL16014176 | 0.68 | PRSS1 (0.38) | PRSS1CTRCF2ALDH1A1 | |
| SCHEMBL11220219 | 0.67 | PRSS1 (0.36) | PRSS1CTRCF2ELANECTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2014196312-A | DERIVATIVE OF 3-ALKYL-5-(4-ALKYL-5-OXO-TETRAHYDROFURAN-2-YL)PYRROLIDIN-2-ONE AS SYNTHETIC INTERMEDIATE FOR RENIN INHIBITOR | ノバルティス アーゲー | 2014-10-16 | — | — | JP | disclosed |
| EP-1948643-B1 | 3-ALKYL-5- (4-ALKYL-5-OXO-TETRAHYDROFURAN-2-YL) PYRROLIDIN-2-ONE DERIVATIVES AS INTERMEDIATES IN THE SYNTHESIS OF RENIN INHIBITORS | NOVARTIS AG (CH) | 2013-06-05 | — | — | EP | disclosed |
| CN-103121995-A | 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors | NOVARTIS AG | 2013-05-29 | — | — | CN | disclosed |
| CN-101111493-B | 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofuran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors | NOVARTIS AG | 2013-02-13 | — | — | CN | disclosed |
| US-8198465-B2 | 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors | NOVARTIS AG (CH) | 2012-06-12 | — | — | US | disclosed |
| US-20100267965-A1 | 3-Alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors | NODEN PHARMA DESIGNATED ACTIVITY COMPANY (IE) | 2010-10-21 | — | — | US | disclosed |
| US-7772405-B2 | 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors | NOVARTIS AG (CH) | 2010-08-10 | — | — | US | disclosed |
| EP-1948643-A2 | 3-ALKYL-5- (4-ALKYL-5-OXO-TETRAHYDROFURAN-2-YL) PYRROLIDIN-2-ONE DERIVATIVES AS INTERMEDIATES IN THE SYNTHESIS OF RENIN INHIBITORS | Novartis AG (CH) | 2008-07-30 | — | — | EP | disclosed |
| CN-101111493-A | 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofuran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors | NOVARTIS AG (CH) | 2008-01-23 | — | — | CN | disclosed |
| WO-2007045420-A3 | 3-ALKYL-5- (4-ALKYL-5-OXO-TETRAHYDROFUTRAN-2-YL) PYRROLIDIN-2-ONE DERIVATIVES AS INTERMEDIATES IN THE SYNTHESIS OF RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007045420-A2 | 3-ALKYL-5- (4-ALKYL-5-OXO-TETRAHYDROFUTRAN-2-YL) PYRROLIDIN-2-ONE DERIVATIVES AS INTERMEDIATES IN THE SYNTHESIS OF RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267965-A1 | 3-Alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one Derivatives as Intermediates in the Synthesis of Renin Inhibitors | REN, AGTR2, AGTR1 | PRSS1 278/4885CTRC 1069/4885F2 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.